featured
Proptosis and Diplopia Response With Teprotumumab and Placebo vs IV Methylprednisolone in Thyroid Eye Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison
JAMA Ophthalmol 2022 Feb 17;[EPub Ahead of Print], RS Douglas, R Dailey, PS Subramanian, G Barbesino, S Ugradar, R Batten, RA Qadeer, C CameronFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.